Abeona Therapeutics Inc Expected to Post Q2 2024 Earnings of ($0.32) Per Share (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEOFree Report) – Investment analysts at Zacks Small Cap upped their Q2 2024 earnings per share estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Tuesday, May 28th. Zacks Small Cap analyst D. Bautz now expects that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.46). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($2.00) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.00) EPS, FY2025 earnings at ($1.11) EPS and FY2026 earnings at ($0.58) EPS.

Other equities research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Stifel Nicolaus initiated coverage on Abeona Therapeutics in a research report on Thursday. They issued a “buy” rating and a $21.00 target price for the company. Finally, Cantor Fitzgerald lowered their price target on Abeona Therapeutics from $28.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, May 16th.

Get Our Latest Report on Abeona Therapeutics

Abeona Therapeutics Price Performance

Shares of ABEO opened at $4.21 on Thursday. The company has a 50-day moving average of $5.63 and a two-hundred day moving average of $5.63. The stock has a market cap of $173.41 million, a price-to-earnings ratio of -1.32 and a beta of 1.59. Abeona Therapeutics has a one year low of $2.83 and a one year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEOGet Free Report) last released its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ABEO. Citigroup Inc. boosted its holdings in Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock worth $1,894,000 after purchasing an additional 250,000 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth about $648,000. Worth Venture Partners LLC boosted its stake in shares of Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 121,969 shares in the last quarter. AIGH Capital Management LLC increased its holdings in shares of Abeona Therapeutics by 77.7% during the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after acquiring an additional 496,278 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling at Abeona Therapeutics

In related news, SVP Brendan M. O’malley bought 8,600 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was bought at an average price of $3.24 per share, with a total value of $27,864.00. Following the purchase, the senior vice president now directly owns 188,718 shares of the company’s stock, valued at approximately $611,446.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Brendan M. O’malley purchased 8,600 shares of Abeona Therapeutics stock in a transaction dated Thursday, April 25th. The stock was acquired at an average cost of $3.24 per share, for a total transaction of $27,864.00. Following the acquisition, the senior vice president now directly owns 188,718 shares in the company, valued at $611,446.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Vishwas Seshadri purchased 10,000 shares of the stock in a transaction that occurred on Thursday, April 25th. The stock was purchased at an average cost of $3.20 per share, with a total value of $32,000.00. Following the purchase, the chief executive officer now owns 538,260 shares in the company, valued at approximately $1,722,432. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 42,758 shares of company stock worth $154,047. 5.30% of the stock is currently owned by company insiders.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.